Meta-analysis of 16 RCTs with 28,168 non-diabetic overweight/obese adults shows GLP-1 and GIP/GLP-1 receptor agonists reduce MACE by 21%, all-cause mortality by 20%, and myocardial infarction risk by 28%.
28% MI reductionGLP-1/GIP receptor agonists reduced myocardial infarction risk by 28% in non-diabetic overweight/obese adults — the first meta-analytic proof of cardiovascular protection in this population
What the researchers found
GLP-1/GIP RAs vs placebo in non-diabetic overweight/obese adults: MACE reduced (OR 0.79, 95% CI 0.71-0.89), all-cause mortality reduced (OR 0.80, 95% CI 0.70-0.92), MI reduced (OR 0.72, 95% CI 0.61-0.86), nonfatal MI reduced (OR 0.72, 95% CI 0.61-0.85). Cardiovascular mortality trend (OR 0.84, 95% CI 0.71-1.01, p=0.06). No significant stroke reduction. No heterogeneity across studies (I²=0 for all outcomes).
Why it matters
Until now, the cardiovascular benefits of GLP-1 RAs were primarily demonstrated in diabetic populations. This meta-analysis proves that these drugs also protect hearts in non-diabetic obese people — a much larger population. This shifts the value proposition of GLP-1 drugs from 'diabetes medication with weight loss benefits' to 'cardiovascular protective therapy for anyone with obesity.'
The numbers in context
Included liraglutide, semaglutide, and tirzepatide trials in non-diabetic overweight/obese populations.
How the study worked
Systematic review and meta-analysis of 16 RCTs (13 GLP-1 RA trials, 3 tirzepatide trials) per PRISMA guidelines. Registered on PROSPERO (CRD42024515966). 28,168 overweight/obese adults without diabetes. Outcomes: MACE, all-cause and cardiovascular mortality, MI, and stroke. Pooled odds ratios with 95% CIs.
Who was studied
Overweight or obese adults without diabetes
What this study cannot tell us
Individual trial follow-up periods may be insufficient to fully capture cardiovascular events. Most participants likely had at least some cardiovascular risk factors beyond obesity. Stroke data are limited. The trend for CV mortality (p=0.06) needs confirmation with longer follow-up. Cost-effectiveness in non-diabetic populations hasn't been established.
How to read the evidence
Strong evidence from a well-conducted, PROSPERO-registered meta-analysis of 16 RCTs with zero heterogeneity across outcomes. The highest level of evidence short of a dedicated cardiovascular outcome trial in non-diabetic obesity.
When this study was published
Published in 2024, providing the most comprehensive pooled analysis to date of cardiovascular outcomes with GLP-1/GIP agonists in non-diabetic obesity.
The bigger picture
This meta-analysis extends the cardiovascular protective umbrella of GLP-1 drugs beyond diabetes. With obesity affecting over 650 million adults worldwide, the potential public health impact is enormous. These findings are likely to reshape obesity treatment guidelines and insurance coverage policies, positioning GLP-1 RAs as cardiovascular-protective medications for the general obese population.
Questions still open
- Is the cardiovascular protection primarily driven by weight loss, or does GLP-1 receptor agonism have independent cardiovascular effects?
- Will longer follow-up confirm the trend toward reduced cardiovascular mortality in non-diabetic obese populations?
Common questions
I don't have diabetes — do GLP-1 drugs still protect my heart?
Does tirzepatide also provide cardiovascular protection?
Read the original research
Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis.
Therapeutic advances in neurological disorders, 17, 17562864241281903
Citation
Stefanou, Maria-Ioanna; Palaiodimou, Lina; Theodorou, Aikaterini; Safouris, Apostolos; Fischer, Urs; Kelly, Peter J; Dawson, Jesse; Katan, Mira; Katsanos, Aristeidis H; Lambadiari, Vaia; Giannopoulos, Sotirios; Alexandrov, Andrei V; Siasos, Gerasimos; Tsivgoulis, Georgios. (2024). Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis.. Therapeutic advances in neurological disorders, 17, 17562864241281903. https://doi.org/10.1177/17562864241281903